Facebook
Twitter
LinkedIn
Forward
Successes, Challenges and Emerging Opportunities of CAR T-Cell Therapy
Activity description
This activity consists of a recorded presentation from the "31st Annual National Clinical Conference" held in Bloomington, Minn., Oct. 17-19, 2022.
The emergence of various novel CAR T-cell therapies has grown exponentially since the first CAR T-cell therapy approval. Over the years, a growing pipeline of CAR T-cell clinical trials have been accumulating, developing strategies to improve the outcomes of CAR T-cell therapies and minimize toxicities. Even though CAR T-cell therapy has only been approved for a limited range of cancer indications, the emerging trend is to develop CAR T-cell treatments for other conditions as well.
These therapies are also still incredibly costly and carry risks that can be life-threatening. Potential solutions to these problems are still in the early stages, but health care professionals are beginning to get a vision of what the future of CAR T-cell therapy might look like. This session discusses CAR T-cell therapy, its current trends, along with the challenges and costs, and what the future may hold for emerging treatment for various conditions.
Provided by
This activity is provided by Optum Health Education.
Commercial support
There was no commercial support for this activity.
Required hardware/software
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
Target Audience
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians, psychologists, social workers, dietitians, and other health care professionals who are interested in CAR T-cell therapies.
Learning Objectives
At the end of this educational activity, participants should be able to:
- Discuss the current trends in CAR T-cell therapies and the diseases for which these treatments are utilized.
- Outline the challenges and costs associated with CAR T-cell therapy.
- Identify the potential future applications of CAR T-cell therapy and the diseases for which this therapy may be beneficial.
Faculty
C. Fred LeMaistre, MD
Senior Vice President, Market Operations
Physician-in-Chief, Hematology
Sarah Cannon
Nashville, TN
About the presenter
C. Frederick LeMaistre, MD, is the senior vice president and physician in chief of hematology and hematopoietic cell therapy, Sarah Cannon Cancer Institute. He received his medical training from Southwestern Medical School, where he also trained in internal medicine. Dr. LeMaistre performed a fellowship in hematology and oncology at the University of Texas Health Science Center at San Antonio. He is board certified in both internal medicine and medical oncology. In 1984, Dr. LeMaistre joined the faculty at the University of Texas Health Science Center in San Antonio, where he established the institution’s marrow transplant program. In 1988, he established the section of experimental therapy in the division of hematology at the M.D. Anderson Cancer Center. In 1993, he founded the Texas Transplant Institute in San Antonio, which now encompasses nationally recognized programs in kidney, liver, and heart transplant, as well as adult and pediatric transplant and cell therapy. In 2009, the Texas Transplant Institute expanded to become the Texas Institute of Medicine and Surgery, a multi-specialty physician organization associated with the Methodist Healthcare System in San Antonio. In 2012, he moved to Nashville to assume his current position. Sarah Cannon is the cancer institute of Hospital Corporation of America (HCA), offering integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. There are over 1.5 million encounters for patients with cancer annually in HCA. Dr. LeMaistre leads the development of overall cancer services for Sarah Cannon as well as the Sarah Cannon Blood Cancer Network, which will provide transplant and cell therapies for over 1,400 patients this year. Dr. LeMaistre has been active in clinical research throughout his career. He is a founding member and past president of the Foundation for the Accreditation of Cell Therapy (FACT). He is also past president of the board of the American Society for Transplant and Cell Therapy (ASTCT).
Planning Committee
Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education
Eden Prairie, MN
Rebecca Gleason, RN, CCM
Activity Manager
Optum Health Education
Eden Prairie, MN
Jennifer Malin, MD, PhD
Senior Vice President and Chief Medical Officer
Optum Health Solutions
Eden Prairie, MN
Tina Rydland, PharmD
President
ArdentCare Solutions
Denver, CO
Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, OptumHealth Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.
The activity faculty and planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
Accreditation Statement
In support of improving patient care, Optum Health Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit designation statements
This activity was planned by and for the health care team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credits for learning and change.
Nurses
The participant will be awarded up to 0.75 contact hour(s) of credit for attendance and completion of supplemental materials.
Nurse practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists/Pharmacy technicians
This activity is approved for 0.75 contact hour(s) ([0.075] CEU) in states that recognize ACPE.
Attending the full program will earn 0.75 contact hour(s).
Unique Activity Number(s): JA0007123-0000-23-081-H01-P/T
Physicians
Optum Health Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PAs
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Case managers
The Commission for Case Manager Certification has approved this program for a maximum of 0.75 clock hour(s) for Certified Case Managers (CCM).
Dietitians
Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit=One CPEU).
If the ac
tivity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour=1 CPEU).
RD's and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner's discretion.
Psychologists and social workers
Participants must have attended the entire Web-based activity and completed an evaluation to receive a certificate. Partial credit is not available.
Psychologists
Optum Health Education is approved by the American Psychological Association (APA) to offer continuing education for psychologists. OptumHealth Education maintains responsibility for this program. 0.75 CE hour.
Social Workers
| As a Jointly Accredited Organization, Optum Health Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Optum Health Education maintains responsibility for this course. Social workers completing this course receive 0.75 enduring continuing education credit. |
Attendance
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.
Available Credit
- 0.75 ACPE - Pharmacists
- 0.75 ACPE - Pharmacy Technicians
- 0.75 AMA - Physicians
- 0.75 ANCC - Nurses
- 0.75 APA - Psychologists
- 0.75 Attendance - General Attendance
- 0.75 CCMC - General - Case Managers
- 0.75 CDR - Dietitians
Prior to beginning this activity, please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
You must be logged into your account to participate in this activity. Get started by clicking the down arrow and then "Start" under “Webcast”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account,” “My Activities.”